Sector News

No quick fix seen for Novartis's troubled Alcon unit

January 12, 2016
Life sciences

(Reuters) – Introduced a decade ago, glaucoma drug Travatan Z has been a powerful driver behind the success of Novartis’s Alcon eye care business, its second biggest division behind the main pharmaceuticals business.

But the drug’s patent expiration last month, the latest in a wave of expiries that have left Alcon vulnerable to generics, brings into sharp focus the unit’s problems, for which analysts say there is no obvious quick fix.

Having taken its first stake in Alcon eight years ago after it was floated by former-owner Nestle, Novartis now acknowledges the ophthalmic division has become its problem child, with too many old products and too little innovation.

Sales have been in decline since 2014 at Alcon, which the Swiss drugmaker completed buying five years ago for nearly $51 billion, slipping 12 percent in the third quarter last year to just $2.35 billion.

Novartis’s total sales in the quarter fell 6 percent to $12.27 billion.

The list of travails is long including laggardly surgical equipment sales, especially in emerging markets like Asia, slumping revenue from intraocular lens (IOL) implants for cataract sufferers and an underperforming over-the-counter contact lens solutions business which could be on the auction block, analysts said.

A management reshuffle has failed to staunch a chronic quarter-on-quarter revenue slide.

Now Novartis Chief Executive Officer Joe Jimenez has promised an innovation-heavy “growth acceleration program” for Alcon which is due to be unveiled on Jan. 27 alongside 2015 results.

Analysts said Jimenez’s crisis response is necessary, but tardy: New product development takes years, meaning Alcon may bump along for the foreseeable future.

“I doubt it will be a quick fix,” said Alistair Campbell, a London-based Berenberg analyst.

“They know they have lagged behind on innovation in both the intraocular lens and drug segments but fixing both will not happen overnight.”

Revenues started to fall in the fourth quarter of 2014 and since last summer Alcon Global Head Jeff George has replaced two thirds of his top managers.

“We’ve seen a significant slowdown in emerging markets, particularly in Asia, which has led to a corresponding drop in our surgical equipment sales,” George said last year.

“We’ve also seen increasing competitive pricing pressure in our IOL business. The third factor … is the increasing generic pressure that we’ve had in our U.S. pharma business.”

In addition to Travatan Z, Patanese, one of Alcon’s allergy drugs, has gone off patent, while Patanol and Pataday also face imminent generic competition, he said.

But a costly turnaround program is hardly timely, given Novartis’s overall revenue could come under pressure with the patent expiry on its blood cancer drug Glivec just as it is stepping up marketing for its new heart-attack drug Entresto.

Disposal of the contact lens solutions businesses, which analysts say ranks second behind Johnson & Johnson, could also be in the offing.

“There are risks of a ramp-up in research and development and marketing spending,” said Deutsche Bank analyst Tim Race. “However, they might just say we are selling parts of the business and not ramp costs up as much as they might otherwise have to.”

Jimenez has left that option open, saying he is amenable to “peeling off underperforming parts of Alcon.” For now, he is committed to Alcon, though his patience is not infinite.

“You have an on-trend business with an aging population,” Jimenez told analysts in October. “If it doesn’t improve, then we’ve got a different conversation.”

By John Miller (Editing by Greg Mahlich)

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.